Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 37 for “"Pertuzumab"”.
-
Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab
… are needed. SPECT/CT imaging with 111In-labeled pertuzumab has previously been shown to sensitively detect trastuzumab-mediated HER2 downregulation as a marker of response to trastuzumab therapy in HER2-overexpressing mouse xenografts. To advance this agent to the clinic, a kit for the …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… alternative HER2-targeted therapies, such as pertuzumab, margetuximab, T-DM1, T-DXd, lapatinib, neratinib, pyrotinib, gefitinib, and tucatinib, have been developed. Nonetheless, despite of their improved effectiveness, de novo and acquired resistance to current treatments are very common in BC …
-
Studien zur Kompatibilität von Parenteralia auf einer pädiatrisch-kardiologischen Intensivstation und zur Stabilität eines monoklonalen Antikörpers
… zweiten Teil der Arbeit wurde die Stabilität von Pertuzumab unter verschiedenen Lagerungsbedingungen untersucht. Pertuzumab ist ein monoklonaler Antikörper, welcher unter dem Handelsnamen Perjeta bei HER2-positivem Brustkrebs angewendet wird. Mit einer umfangreichen Auswahl an analytischen …
-
HER receptor-mediated dynamic signalling in breast cancer cells
… antibodies were investigated – trastuzumab and pertuzumab. Trastuzumab not only inhibited the growth of HER-2 over-expressing MCF-7/HER2- 18 cells and BT474 cells but also that of EGF-driven MCF-7 cells which expressed low/moderate HER-2 levels. Pertuzumab blocked the growth of both MCF-7 and …
-
Antagonism Between Trastuzumab and Oncolytic VSV is Overcome by Conjugation to a Microtubule Destabilizer
… (trastuzumab), by preventing HER2 dimerization (pertuzumab), or via targeted delivery of a cytotoxic payload (trastuzumab emtansine). Although these therapies are successful in some cases, acquired and inherent resistance to these therapeutics remain a treatment hurdle. Oncolytic viruses (OVs) …
-
Molecular Imaging as a Tool for Predicting and Monitoring Response of Breast Cancer to Trastuzumab (Herceptin(R))
… MDA-MB-361 xenografts administered 111In-DTPA-pertuzumab. Tumour uptake of 111In-DTPA-pertuzumab was reduced by 53% in mice treated for 3 days with trastuzumab (P<0.05) associated with an early molecular response to the drug. Furthermore, tumour uptake of 111In-DTPA-pertuzumab was reduced by …
-
Rational design, characterization and in vivo studies of antibody mimics against HER2
… approach based on molecular interactions of HER2-Pertuzumab complex and Knob-Socket model can be developed to design antibody mimics for targeting HER2. All designed antibody mimics were simulated and docked with HER2 using Molecular Operating Environment (MOE) software to estimate binding energy …
-
Development and Characterization of Antibody-Gold Nanocluster Conjugates
… were explored for DBCO installation on wild-type pertuzumab (WT Pertu) and engineered pertuzumab (Eng Pertu), resulting in four distinct antibody-AuNC conjugates. A cathepsin-cleavable linker was additionally explored as a preliminary extension toward an antibody-drug conjugate-like release …
-
Leveraging Antibodies for Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Cancer
… tomography (PET) imaging agent, 89Zr-DFO-pertuzumab, in mouse models of human breast cancer. In the second part, we developed two imaging agents for ovarian cancer, 89Zr-DFO-AR20.5 for PET and ssB43.13-IR800 for near-infrared fluorescence imaging and evaluated their in vivo performance in …
-
EGFR and HER2-targeted radioimmunoconjugates for theranostic molecular imaging and Auger electron radioimmunotherapy of breast cancer
… (BC) and confer a poor prognosis. HER2-targeted pertuzumab Fab fragments were modified with hexahistidine peptides for radiolabelling with 99mTc and EGFR-targeted panitumumab with DOTA chelators for radiolabelling with 111In for SPECT imaging and Auger electron (AE) radioimmunotherapy (RIT). …
-
Η σημασία του HER2 στο αδενοκαρκίνωμα παχέος εντέρου
… tratuzumab – lapatinib και trastuzumab – pertuzumab αντίστοιχα. Όμως, είναι απαραίτητο να υπάρξουν δεδομένα από μεγαλύτερες κλινικές δοκιμές προκειμένω η anti-HER2 θεραπεία να ενσωματωθεί ως καθιερωμένη θεραπεία για τον καρκίνο του παχέος εντέρου. Τέλος, με βάση τα δεδομένα ως τώρα, ο …
-
Einfluss einer kardiotoxischen Chemotherapie auf kardiovaskuläre Biomarker im klinischen Verlauf
… Patientinnen wurden ergänzend Trastuzumab und Pertuzumab gegeben. Bei allen Patientinnen wurden kardiale Biomarker, N-terminales pro-B-Typ natriuretisches Peptid (NT-proBNP) und hoch-sensitives Troponin T (hsTrop T), Echokardiographie, hämodynamische Parameter, sowie Anämie und Eisenmangel …
-
Role of HER-targeted tyrosine kinase inhibitors in the treatment of high grade serous ovarian cancer
… compared with the anti-HER2 mAbs trastuzumab and pertuzumab. The outcomes of modulation of EGFR, HER2 and HER3 expression on treatment sensitivity were also investigated, along with gene expression differences upon treatment. The TKIs were found to be effective in inhibiting proliferation, …
-
Ο ρόλος του HER2 στη χειρουργική αντιμετώπιση του καρκίνου του μαστού
… του διπλού αποκλεισμού HER2 (trastuzumab και pertuzumab) όσο και η χρήση συμπλεγμάτων αντίσωμα-φαρμάκου (T-DM1, T-DXd) βελτιώνουν σημαντικά την επιβίωση και οδηγούν σε αυξημένο ποσοστό πλήρους παθολογοανατομικής ανταπόκρισης (pCR). Η επίτευξη της pCR οδήγησε στην αποκλιμάκωση της χειρουργικής …
-
Costo-efectividad de la biopsia líquida para definir cambio farmacológico en cáncer de mama HER2 + avanzado en Colombia
… and second lines of treatment (Trastuzumab, Pertuzumab, Docetaxel and TDM1 respectively), resistance, outcomes, sensitivity and specificity of the test. The effectiveness was measured by QALYs and the costs were obtained from databases of national validity, suppliers, Drug Price Information …
-
Metabolic vulnerability in HER2-positive Breast Cancer
… including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an antibody-drug conjugate (trastuzumab emtansine), have significantly prolonged the overall survival of HER2-positive breast cancer patients. However, almost all patients develop …
-
The Development of Novel Radioimmunoconjugates for the PET Imaging and Radioimmunotherapy of Cancer
… reagent, PFP-bisN3, to prepare [89Zr]Zr-SSKDFO-pertuzumab for visualizing HER2+ breast cancer. Further, we introduce a new mAb with a catalytic domain that allows for the site-selective bioconjugation of chelators to yield [177Lu]Lu-CHX-A”-DTPA-PODS-HER2DVD for targeting HER2+ breast cancer. For …
-
Αποτελεσματικότητα και ασφάλεια των στοχευμένων θεραπειών έναντι του υποδοχέα τύπου 2 του ανθρώπινου επιδερμικού αυξητικού παράγοντα (HER2) στον ανεγχείρητο ή μεταστατικό καρκίνο του στομάχου και της γαστροοισοφαγικής συμβολής: Μία συστηματική ανασκόπηση.
… (27 με trastuzumab, 5 με lapatinib, 2 με pertuzumab, 2 με margetuximab και από μία με trastuzumab-emtasine, afatinib, dacomitinib, MCLA-128, MM-111, AZD8931. Οι περισσότερες (n=28) ήταν δοκιμές φάσεως 2. Η πλειονότητα δεν ήταν τυχαιοποιημένες (n=30), 28 δεν είχαν ομάδα ελέγχου, τρείς ήταν …
-
Διερεύνηση της καρδιακής δυσλειτουργίας σε γυναίκες με μεταστατικό καρκίνο του μαστού υπό θεραπεία με μονοκλωνικά αντισώματα
… of cardiovascular disease. The study drugs were Pertuzumab plus Trastuzumab plus Docetaxel. A control group was also used for the study purposes. Patient follow-up began before treatment and was performed every three months for a maximum of 2 years. Results: The rate of cardiotoxicity was 10.2% …
-
Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR using Bispecific Radioimmunoconjugates
… the target for immunotherapy with trastuzumab, pertuzumab, and trastuzumab-emtansine (T-DM1). Despite improvements in survival, resistance to HER2-targeted therapies remains a major problem. One resistance mechanism is loss of HER2 and increased EGFR. Additionally, intratumoral HER2 …
Page 1 of 2